GO:0031783 type 5 melanocortin receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031783 (type 5 melanocortin receptor binding) is a molecular_function term describing the binding of a ligand to the type 5 melanocortin receptor (MC5R), a member of the melanocortin receptor family.
• Melanocortin receptors, including MC5R, are G-protein-coupled receptors that bind melanocortin peptides such as alpha-MSH and ACTH, and their ligand-binding determinants have been mapped for several subtypes.
• Ligand binding to melanocortin receptor subtypes can be co-operatively regulated, indicating interacting binding sites and complex allosteric behavior.
• MC5R is expressed in peripheral tissues and has been implicated in exocrine gland function, energy homeostasis, and hepatic metabolic control via melanocortin-dependent mTOR activation.
• Dysregulation of melanocortin signaling is linked to obesity, metabolic disorders, and hepatocellular carcinoma, making MC5R binding a potential therapeutic target.
• CRISPR-based knockout, point-mutation, and knock-in models enable precise dissection of MC5R ligand-binding residues and downstream signaling in disease-relevant contexts.
Description
GO:0031783, type 5 melanocortin receptor binding, is a molecular_function term that describes the binding of a ligand to the type 5 melanocortin receptor (MC5R), a member of the melanocortin receptor family. Melanocortin receptors are G-protein-coupled receptors (GPCRs) that mediate diverse physiological effects of melanocortin peptides, including alpha-melanocyte-stimulating hormone (alpha-MSH) and adrenocorticotropic hormone (ACTH). The type 5 receptor (MC5R) is one of five melanocortin receptor subtypes (MC1R-MC5R) and is distinguished by its wide peripheral expression and roles in exocrine function and metabolic regulation. Understanding the molecular determinants of ligand binding to MC5R is essential for drug discovery and for interpreting how natural mutations alter receptor function. Ligand binding to melanocortin receptors is not a simple one-step event; evidence from receptor subtype studies indicates co-operative regulation and interacting binding sites, which can modulate affinity and signaling bias. For MC4R, a close homolog, gain-of-function variants show signaling bias and protect against obesity, illustrating how subtle changes in ligand-receptor interaction can have profound physiological consequences. Although MC5R is less studied than MC4R, its involvement in hepatic ER homeostasis via melanocortin-dependent mTOR activation highlights its importance in systemic metabolism. Researchers studying GO:0031783 aim to define which ligands bind MC5R, how binding affinity is regulated, and how this binding translates into downstream signaling in health and disease. This article synthesizes authoritative QuickGO annotation and verified PubMed literature to provide a research-grade overview of the term, its mechanisms, associated genes, disease links, and experimental models including CRISPR-based approaches.
type 5 melanocortin receptor binding At A Glance
| GO ID | GO:0031783 |
|---|---|
| GO term | type 5 melanocortin receptor binding |
| Ontology | molecular_function |
| Synonym | type 5 melanocortin receptor ligand |
| Definition | Binding to a type 5 melanocortin receptor. |
| Major function | Mediates physical interaction between a ligand and MC5R, initiating or modulating receptor activity. |
| Related receptor | MC5R (melanocortin 5 receptor), a G-protein-coupled receptor. |
| Typical ligands | Melanocortin peptides such as alpha-MSH and ACTH, and synthetic melanocortin analogs. |
| Research relevance | Target for metabolic, exocrine, and inflammatory disease studies; enables ligand-binding and signaling-bias investigations. |
What Is GO:0031783?
In simple terms, GO:0031783 describes the act of a molecule (a ligand) attaching to the type 5 melanocortin receptor (MC5R). According to the Gene Ontology, this term is defined as 'Binding to a type 5 melanocortin receptor.' It is a molecular_function term, meaning it describes a specific activity at the molecular level rather than a biological process or cellular component. The synonym 'type 5 melanocortin receptor ligand' reflects the role of the binding partner. This term is used when annotating gene products that physically interact with MC5R, such as melanocortin peptides or synthetic ligands, and it does not by itself imply downstream signaling, which would be captured by separate GO terms.
Why Is type 5 melanocortin receptor binding Important in Cell Biology?
GO:0031783 is important because MC5R binding is a nodal point for melanocortin signaling in peripheral tissues, influencing exocrine gland secretion, energy homeostasis, and hepatic metabolic control. Dysregulated melanocortin signaling has been linked to obesity and metabolic disorders, and gain-of-function MC4R variants protect against obesity, underscoring the therapeutic potential of targeting melanocortin receptor binding. In cancer, metabolic dysregulation is a hallmark of hepatocellular carcinoma, and melanocortin-dependent mTOR activation in the liver suggests that MC5R binding may contribute to hepatic metabolic reprogramming. Furthermore, melanocortin receptor antagonists are being explored for depression and anxiety, indicating that modulating receptor binding has broad neuropsychiatric relevance. Thus, understanding the molecular details of MC5R binding can inform drug design and functional genomics.
• MC5R binding regulates exocrine gland function and energy homeostasis.
• Melanocortin-dependent mTOR activation in the liver links MC5R binding to hepatic ER homeostasis.
• Gain-of-function MC4R variants protect against obesity, highlighting melanocortin receptor binding as a therapeutic axis.
• Melanocortin receptor antagonists are investigated for depression and anxiety, showing the clinical relevance of receptor binding modulation.
• Metabolic dysregulation in hepatocellular carcinoma involves melanocortin signaling pathways.
• Co-operative ligand binding to melanocortin receptor subtypes suggests complex allosteric regulation that can be exploited pharmacologically.
• Molecular determinants of ligand binding to melanocortin receptors have been mapped, providing templates for MC5R studies.
• MC5R is a potential target for anti-obesity and metabolic syndrome therapies.
• CRISPR models enable precise testing of MC5R binding residues in disease models.
• Understanding MC5R binding can guide development of biased ligands with improved safety profiles.
Molecular Mechanism of type 5 melanocortin receptor binding
Ligand recognition and binding pocket
In simple terms: The ligand docks into a specific pocket on the MC5R receptor, like a key fitting a lock.
Melanocortin receptors share a conserved binding pocket formed by transmembrane helices. For MC4R, molecular determinants of ligand binding have been identified, including charged residues that interact with the core melanocortin peptide sequence. MC5R is expected to use a similar binding mode, with subtype-specific residues conferring selectivity for alpha-MSH and ACTH. The binding pocket accommodates the conserved His-Phe-Arg-Trp motif of melanocortin peptides, which is critical for receptor activation.
Co-operative regulation and allosteric interactions
In simple terms: Binding of one ligand can change how easily another ligand binds, due to interacting sites on the receptor.
Evidence from melanocortin receptor subtypes indicates co-operative regulation of ligand binding, suggesting the presence of interacting binding sites. This means that MC5R binding may not follow simple Michaelis-Menten kinetics; instead, allosteric modulation can alter affinity and efficacy. Such co-operativity has implications for drug design, as biased ligands could stabilize specific receptor conformations.
G-protein coupling and downstream signaling
In simple terms: Once the ligand binds, the receptor activates G-proteins that trigger signaling inside the cell.
MC5R is a G-protein-coupled receptor that primarily couples to Gs, leading to adenylyl cyclase activation and cAMP accumulation. However, signaling bias has been observed for MC4R variants, where different ligands preferentially activate distinct pathways. For MC5R, the link between binding and downstream effects such as mTOR activation in the liver has been demonstrated, indicating that MC5R binding can influence metabolic signaling.
Regulation by accessory proteins and cellular context
In simple terms: Other proteins and the cell environment can tweak how well the receptor binds its ligand.
Melanocortin receptor binding can be modulated by accessory proteins, post-translational modifications, and membrane lipid composition. In the liver, food perception primes hepatic ER homeostasis via melanocortin-dependent control of mTOR activation, showing that physiological context regulates melanocortin signaling. Additionally, inflammatory states can alter receptor expression and ligand availability, indirectly affecting MC5R binding.
Key Genes Involved in GO:0031783 type 5 melanocortin receptor binding
The following genes and proteins are directly or indirectly involved in type 5 melanocortin receptor binding and its downstream biology.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MC5R | Encodes the type 5 melanocortin receptor, the direct binding target of GO:0031783. | Primary gene for ligand-binding and signaling studies; knockout models reveal physiological roles. |
| POMC | Precursor of melanocortin peptides including alpha-MSH and ACTH, which are ligands for MC5R. | Provides endogenous ligands; mutations affect ligand availability and receptor binding. |
| MC4R | Homologous melanocortin receptor; shares ligands and signaling pathways with MC5R. | Model for understanding binding determinants and signaling bias; gain-of-function variants protect against obesity. |
| MC1R | Melanocortin receptor subtype with distinct ligand selectivity. | Comparative studies inform subtype-specific binding mechanisms. |
| MC3R | Melanocortin receptor involved in energy homeostasis. | Contributes to melanocortin system redundancy and ligand cross-reactivity. |
| MC2R | ACTH receptor; defines the melanocortin receptor family. | Provides evolutionary context for MC5R binding. |
| MRAP | Melanocortin receptor accessory protein, required for MC2R function. | May modulate MC5R trafficking and binding; potential accessory factor. |
| AGRP | Agouti-related protein, an endogenous antagonist of melanocortin receptors. | Modulates MC5R binding and signaling; relevant to energy balance. |
| ASIP | Agouti signaling protein, antagonist at melanocortin receptors. | Influences ligand competition at MC5R. |
| MTOR | Kinase downstream of melanocortin signaling in the liver. | Links MC5R binding to hepatic ER homeostasis and metabolism. |
| PERK | ER stress sensor modulated by melanocortin signaling. | Connects MC5R binding to ER stress and inflammation. |
| IRE1 | ER stress sensor in the unfolded protein response. | Interacts with melanocortin-dependent pathways in liver and spinal cord. |
| NLRP3 | Inflammasome component upregulated in inflammatory states. | Potential downstream effector of melanocortin signaling in inflammation. |
| LCN2 | Lipocalin-2, an inflammatory mediator. | Modulated by melanocortin pathways in neuroinflammation. |
| GNAS | G-protein alpha subunit mediating cAMP signaling from MC5R. | Essential for downstream signaling after ligand binding. |
| PRKACA | Protein kinase A catalytic subunit, activated by cAMP. | Transduces MC5R binding signals to metabolic targets. |
| CREB1 | Transcription factor activated by cAMP/PKA. | Mediates gene expression changes downstream of MC5R binding. |
| STAT3 | Transcription factor involved in cytokine and metabolic signaling. | Cross-talks with melanocortin pathways in liver and inflammation. |
How Is type 5 melanocortin receptor binding Regulated?
Type 5 melanocortin receptor binding is regulated at multiple levels. Ligand availability is controlled by the expression and processing of POMC, which yields alpha-MSH and ACTH. Endogenous antagonists such as AGRP and ASIP can compete with agonists for the binding pocket, modulating receptor activation. Receptor expression levels and trafficking to the cell surface are influenced by accessory proteins like MRAP and by post-translational modifications. In the liver, melanocortin-dependent control of mTOR activation links nutritional status to receptor signaling, indicating metabolic regulation of the pathway. Additionally, inflammatory mediators such as lipocalin-2 and NLRP3 can indirectly affect melanocortin signaling in the spinal cord, suggesting that inflammation modulates receptor binding or downstream responses. Co-operative binding interactions among receptor subtypes further add to the complexity of regulation.
type 5 melanocortin receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MC5R | Metabolic disorders, exocrine dysfunction | MC5R knockout and knock-in mice; cell-based binding assays. |
| MC4R | Obesity, signaling bias | MC4R gain-of-function knock-in models; cAMP assays. |
| POMC | Obesity, adrenal insufficiency | POMC knockout models; ligand supplementation studies. |
| MTOR | Hepatocellular carcinoma, metabolic dysregulation | Liver-specific mTOR knockout; MC5R ligand treatment. |
| NLRP3 | Neuroinflammation, morphine tolerance | NLRP3 knockout mice; MC5R agonist treatment. |
Metabolic disorders and obesity
Melanocortin signaling is a central regulator of energy homeostasis. Gain-of-function MC4R variants show signaling bias and protect against obesity, demonstrating that altered ligand binding at melanocortin receptors can have anti-obesity effects. Although MC5R is less studied in obesity, its role in exocrine function and hepatic metabolism suggests that MC5R binding may contribute to metabolic regulation. Targeting MC5R binding could therefore offer a therapeutic strategy for metabolic syndrome.
Hepatocellular carcinoma and liver metabolism
Metabolic dysregulation is a hallmark of hepatocellular carcinoma (HCC), and melanocortin-dependent mTOR activation in the liver links food perception to hepatic ER homeostasis. This suggests that MC5R binding and downstream signaling may influence HCC progression through metabolic reprogramming. Investigating MC5R binding in liver cells could reveal new targets for HCC therapy.
Neuroinflammation and pain
Melanocortin receptors are expressed in the central nervous system, and their binding can modulate neuroinflammatory pathways. Astrocyte PERK and IRE1 signaling contributes to morphine tolerance and hyperalgesia through upregulation of lipocalin-2 and NLRP3 inflammasome, processes that may intersect with melanocortin signaling. Thus, MC5R binding could be relevant to pain and neuroinflammatory conditions.
Psychiatric disorders
Melanocortin-4 receptor antagonists are being developed for depression and anxiety disorders, indicating that modulating melanocortin receptor binding has neuropsychiatric applications. Although MC5R is not the primary target in these studies, the broader melanocortin system is implicated, and understanding MC5R binding may inform future therapeutic design.
From type 5 melanocortin receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does MC5R mediate specific ligand binding in vivo? | MC5R knockout mouse or cell line. |
| Which residues determine ligand selectivity? | Point-mutation knock-in of MC5R binding pocket residues. |
| How does a disease-associated MC5R variant affect signaling? | Knock-in of the variant allele in cell lines or mice. |
| Where is MC5R expressed and trafficked? | Tagged knock-in of MC5R with fluorescent or epitope tag. |
| Does MC5R overexpression alter metabolic signaling? | Overexpression of MC5R in hepatocytes or adipocytes. |
| Can CRISPR screening identify modifiers of MC5R binding? | Genome-wide CRISPR library screening in MC5R-expressing cells. |
How to Study the type 5 melanocortin receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Affinity and kinetics of ligand-MC5R interaction | Screening synthetic melanocortin analogs. |
| cAMP assay | Gs-mediated signaling after receptor activation | Evaluating agonist efficacy and signaling bias. |
| Beta-arrestin recruitment | G-protein-independent signaling | Assessing biased agonism at MC5R. |
| CRISPR knockout | Loss-of-function effects on binding and signaling | Identifying essential genes for MC5R function. |
| CRISPR knock-in | Effect of specific mutations on binding | Mapping binding pocket residues. |
| RNA-seq | Transcriptional changes downstream of MC5R binding | Discovering gene expression programs. |
| Proteomics | Protein expression and post-translational modifications | Mapping signaling networks. |
| Metabolic phenotyping | Whole-body energy and glucose homeostasis | Testing MC5R ligands in obesity models. |
Ligand binding assays
Radioligand binding assays using iodinated alpha-MSH or ACTH analogs are standard for measuring MC5R binding affinity and competition. These assays can be performed on membrane preparations from cells expressing recombinant MC5R or on tissue homogenates. Co-operative binding can be detected by nonlinear Scatchard analysis.
Cell-based signaling assays
cAMP accumulation assays are used to measure MC5R activation following ligand binding. Reporter gene assays driven by cAMP-response elements (CRE-luciferase) provide a sensitive readout of Gs coupling. Signaling bias can be assessed by comparing cAMP, beta-arrestin recruitment, and ERK phosphorylation.
Genetic and CRISPR screens
CRISPR knockout and knock-in models enable functional dissection of MC5R binding determinants. Genome-wide CRISPR screens can identify genes that modify MC5R ligand binding or downstream signaling, revealing novel regulators. These approaches are complemented by RNA-seq and proteomics to map transcriptional and proteomic changes.
In vivo metabolic phenotyping
Mouse models with MC5R knockout or knock-in mutations can be subjected to metabolic phenotyping, including glucose tolerance tests, insulin tolerance tests, and body composition analysis. Liver-specific manipulations can assess the role of MC5R binding in hepatic ER homeostasis and mTOR activation.
How CRISPR Can Be Used to Study GO:0031783 type 5 melanocortin receptor binding
Knockout
CRISPR knockout of MC5R or its ligands (e.g., POMC) can abolish type 5 melanocortin receptor binding, providing a clean background to test ligand specificity and downstream effects. Knockout cell lines are valuable for validating antibody specificity and for re-expression studies. In vivo, MC5R knockout mice display altered exocrine function and metabolic phenotypes, confirming the physiological relevance of the binding event.
Point Mutation
Point mutations in the MC5R binding pocket can be introduced using CRISPR base editing or homology-directed repair to test the contribution of individual residues to ligand binding. Such models are essential for understanding subtype selectivity and for mimicking natural variants. For example, mutations identified in MC4R that affect binding can be mirrored in MC5R to compare structure-function relationships.
Knock-in
Knock-in of tagged MC5R (e.g., FLAG or GFP) allows visualization and purification of the receptor for binding assays. Knock-in of disease-associated variants can model how mutations alter ligand binding and signaling in a physiological context. This approach is particularly useful for studying signaling bias, as seen with MC4R variants.
Overexpression
Overexpression of MC5R in heterologous cells (e.g., HEK293) is a standard method to obtain high receptor density for binding studies. Overexpression in disease-relevant cells, such as hepatocytes, can amplify downstream signaling and reveal metabolic effects. However, overexpression may saturate accessory proteins, so results should be interpreted with caution.
How EDITGENE Supports type 5 melanocortin receptor binding Research
Researchers studying type 5 melanocortin receptor binding-related genes often need to determine whether a candidate gene is causally involved in ligand binding, signaling, or disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling functional validation of MC5R and its interaction partners.
Contact EDITGENE today to design your custom CRISPR model for type 5 melanocortin receptor binding research.
Frequently Asked Questions About type 5 melanocortin receptor binding
What is type 5 melanocortin receptor binding?
Type 5 melanocortin receptor binding (GO:0031783) is the molecular function of a ligand physically interacting with the type 5 melanocortin receptor (MC5R), a G-protein-coupled receptor.
What genes are involved in type 5 melanocortin receptor binding?
The primary gene is MC5R, which encodes the receptor. Ligands are derived from POMC, and related receptors include MC1R, MC3R, and MC4R.
What diseases are associated with MC5R binding?
MC5R binding has been linked to metabolic disorders, exocrine dysfunction, and potentially hepatocellular carcinoma through melanocortin-dependent mTOR activation.
How can I study type 5 melanocortin receptor binding?
Common methods include radioligand binding assays, cAMP signaling assays, and CRISPR-based knockout or knock-in models.
What is the role of MC5R in obesity?
MC5R is expressed in peripheral tissues and may influence energy homeostasis, though its role in obesity is less defined than MC4R, which has gain-of-function variants that protect against obesity.
Can CRISPR be used to study MC5R binding?
Yes, CRISPR knockout, point mutation, and knock-in models allow precise dissection of MC5R binding determinants and downstream signaling.
What are the endogenous ligands for MC5R?
Endogenous ligands include alpha-melanocyte-stimulating hormone (alpha-MSH) and adrenocorticotropic hormone (ACTH), derived from the POMC precursor.
How is MC5R binding regulated?
Regulation occurs via ligand availability, endogenous antagonists like AGRP, receptor trafficking, and co-operative interactions among receptor subtypes.
What is the difference between MC4R and MC5R binding?
MC4R is primarily involved in central energy homeostasis and has well-characterized gain-of-function variants, while MC5R is more peripherally expressed and involved in exocrine function and hepatic metabolism.
What cell models are available for MC5R research?
EDITGENE provides CRISPR knockout, point mutation, knock-in, and overexpression cell models for MC5R and related genes, along with library screening and bioinformatics services.
Conclusion
GO:0031783, type 5 melanocortin receptor binding, represents a critical molecular interaction that initiates melanocortin signaling at MC5R. Despite being less studied than MC4R, MC5R binding has important implications for exocrine function, energy homeostasis, and hepatic metabolism, with potential links to metabolic disorders and hepatocellular carcinoma. Advances in CRISPR-based models and binding assays are enabling precise dissection of the molecular determinants and regulatory mechanisms of this interaction. Continued research into MC5R binding may uncover new therapeutic opportunities for metabolic and inflammatory diseases.
References
- 1. Du D et al.. 2022. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma.. Acta Pharm Sin B 12(2):558-580 PMID: 35256934
- 2. Lotta LA et al.. 2019. Human Gain-of-Function MC4R Variants Show Signaling Bias and Protect against Obesity.. Cell 177(3):597-607.e9 PMID: 31002796
- 3. Chaki S et al.. 2007. Melanocortin-4 receptor antagonists for the treatment of depression and anxiety disorders.. Curr Top Med Chem 7(11):1145-51 PMID: 17584135
- 4. Brandt C et al.. 2018. Food Perception Primes Hepatic ER Homeostasis via Melanocortin-Dependent Control of mTOR Activation.. Cell 175(5):1321-1335.e20 PMID: 30445039
- 5. Yang YK et al.. 2000. Molecular determinants of ligand binding to the human melanocortin-4 receptor.. Biochemistry 39(48):14900-11 PMID: 11101306
- 6. Wang B et al.. 2024. Astrocyte PERK and IRE1 Signaling Contributes to Morphine Tolerance and Hyperalgesia through Upregulation of Lipocalin-2 and NLRP3 Inflammasome in the Rodent Spinal Cord.. Anesthesiology 140(3):558-577 PMID: 38079113
- 7. Kopanchuk S et al.. 2005. Co-operative regulation of ligand binding to melanocortin receptor subtypes: evidence for interacting binding sites.. Eur J Pharmacol 512(2-3):85-95 PMID: 15840392
- 8. Voisey J et al.. 2003. Melanocortins and their receptors and antagonists.. Curr Drug Targets 4(7):586-97 PMID: 14535656
